eeBxb15801 bp60012001800240030003600420048005400oriL4440AmpR promoterpBRforEcolac UV5 promoterM13/pUC ReverseCMV enhancerCMV promoterSP6 promoterBxb1 integraseSV40 poly(A) signalf1 oriAmpRloxP

基本信息

The eeBxb1 designed for expressing evolved and engineered Bxb1 in the mammalian cells
载体名称
eeBxb1
载体抗性
Ampicillin
载体长度
5801 bp
载体类型
Mammalian Expression Vectors
启动子
CMV
感受态
DH10B
培养温度
37℃

质粒操作方法

质粒复溶方法

  1. 发货形式:质粒干粉,常温运输,收到后请于 -20 ℃ 保存,先转化提质粒再使用。
  2. 收到干粉后先 5000 rpm 离心 1 min,加入 20 μl ddH₂O 溶解。质粒复测浓度与标称值可能有差距,这通常来自干粉在管中的位置、复溶效率、测量偏差与管壁吸附,建议先转化提质粒后再使用。
  3. 取 1 支 100 μl 感受态细胞冰上解冻 10 min,加入 2 μl 质粒,冰浴 30 min,42 ℃ 热激 60 s(不要摇动),再冰浴 2 min。
  4. 加入 900 μl 无抗生素 LB 液体培养基,180 rpm、37 ℃ 振荡培养 45 min(30 ℃ 培养 1–1.5 h)。
  5. 6000 rpm 离心 5 min,保留约 100 μl 上清重悬菌体,涂布到对应抗性的 LB 平板。
  6. 平板倒置 37 ℃ 培养 14 h(30 ℃ 则 20 h)。菌落过多可稀释质粒后再转化;无菌落可增加至 10 μl 质粒。建议先转克隆感受态、重提质粒后再导入表达感受态。
  7. 挑取单菌落接种 LB 液体培养基,加入对应抗生素,220 rpm 振荡培养 14 h,按试剂盒说明提取质粒。

通用质粒转化方法

  1. 取100 μL感受态细胞置于冰上解冻10 min,加入2 μL质粒,冰浴30 min;随后42 ℃热激60 s,期间不要晃动,再冰浴2 min。
  2. 加入900 μL无抗LB液体培养基,37 ℃、180 rpm振荡培养45 min(30 ℃条件下则培养1–1.5 h)。
  3. 6000 rpm离心5 min,弃上清,仅保留100 μL上清重悬菌体沉淀,涂布于对应质粒抗性的LB平板上。
  4. 平板倒置培养,37 ℃培养14 h,或30 ℃培养20 h。
  5. 挑取单菌落至LB液体培养基中,加入对应抗生素,220 rpm振荡培养14 h;根据实验需求及质粒提取试剂盒说明书提取质粒。

参考文献

  • Pandey S, Gao XD, Krasnow NA, et al. Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat Biomed Eng. Published online June 10, 2024. doi:10.1038/s41551-024-01227-1

eeBxb1 质粒 (编号: V017502) 注释

LOCUS       eeBxb1                  5801 bp    DNA     circular SYN 26-DEC-2025
DEFINITION  Plasmid for expressing evolved and engineered Bxb1 in the mammalian 
            cells.
ACCESSION   .
VERSION     .
KEYWORDS    .
SOURCE      synthetic DNA construct
  ORGANISM  synthetic DNA construct
REFERENCE   1  (bases 1 to 5801)
  AUTHORS   Pandey S, Gao XD, Krasnow NA, McElroy A, Tao YA, Duby JE, Steinbeck 
            BJ, McCreary J, Pierce SE, Tolar J, Meissner TB, Chaikof EL, Osborn 
            MJ, Liu DR
  TITLE     Efficient site-specific integration of large genes in mammalian 
            cells via continuously evolved recombinases and prime editing.
  JOURNAL   Nat Biomed Eng. 2024 Jun 10. doi: 10.1038/s41551-024-01227-1.
  PUBMED    38858586
REFERENCE   2  (bases 1 to 5801)
  AUTHORS   .
  TITLE     Direct Submission
COMMENT     SGRef: number: 1; type: "Journal Article"; journalName: "Nat Biomed 
            Eng. 2024 Jun 10. doi: 10.1038/s41551-024-01227-1."
COMMENT     Sequence Label: eeBxb1
FEATURES             Location/Qualifiers
     source          1..5801
                     /mol_type="other DNA"
                     /organism="synthetic DNA construct"
     rep_origin      1..589
                     /direction=RIGHT
                     /label=ori
                     /note="high-copy-number ColE1/pMB1/pBR322/pUC origin of 
                     replication"
     primer_bind     490..509
                     /label=pBR322ori-F
                     /note="pBR322 origin, forward primer"
     primer_bind     743..760
                     /label=L4440
                     /note="L4440 vector, forward primer"
     promoter        complement(834..938)
                     /gene="bla"
                     /label=AmpR promoter
     primer_bind     1006..1024
                     /label=pBRforEco
                     /note="pBR322 vectors, upsteam of EcoRI site, forward
                     primer"
     promoter        1051..1081
                     /label=lac UV5 promoter
                     /note="E. coli lac promoter with an ""up"" mutation"
     protein_bind    1089..1105
                     /label=lac operator
                     /bound_moiety="lac repressor encoded by lacI"
                     /note="The lac repressor binds to the lac operator to
                     inhibit transcription in E. coli. This inhibition can be 
                     relieved by adding lactose or 
                     isopropyl-beta-D-thiogalactopyranoside (IPTG)."
     primer_bind     1094..1116
                     /label=M13/pUC Reverse
                     /note="In lacZ gene"
     enhancer        1135..1438
                     /label=CMV enhancer
                     /note="human cytomegalovirus immediate early enhancer"
     promoter        1439..1642
                     /label=CMV promoter
                     /note="human cytomegalovirus (CMV) immediate early
                     promoter"
     primer_bind     1593..1613
                     /label=CMV-F
                     /note="Human CMV immediate early promoter, forward primer"
     primer_bind     1639..1663
                     /label=LNCX
                     /note="Human CMV promoter, forward primer"
     promoter        1758..1776
                     /label=SP6 promoter
                     /note="promoter for bacteriophage SP6 RNA polymerase"
     primer_bind     1758..1775
                     /label=SP6
                     /note="SP6 promoter, forward primer"
     CDS             1814..3316
                     /codon_start=1
                     /transl_table=11
                     /gene="Bxb1"
                     /product="Bxb1 integrase"
                     /label=Bxb1 integrase
                     /note="Bxb1 large serine integrase from Mycobacterium 
                     bacteriophage Bxb1 (Ghosh et al. 2003)."
                     /protein_id="AFF61396.1"
                     /translation="MRALVVIRLSRVTDATTSPERQLESCQQLCAQRGWDVVGVAEDLD
                     VSGAVDPFDRKRRPNLARWLAFEEQPFDAIVAYRVDRLTRSIRHLQQLVHWAEDHKKLV
                     VSATEAHFDTTTPFAAVVIALMGTVAQMELEAIKERNRSAAHFNIRAGKYRGSLPPWGY
                     LPTRVDGEWRLVPDPVQRERILEVYHRVVDNHEPLHLVAHDLNRRGVLSPKDYFAQLQG
                     REPQGRKWSATALKRSMISEAMLGYATLNGKTVRDDDGAPLVRAEPILTREQLEALRAE
                     LVKTSRAKPAVSTPSLLLRVLFCAVCGEPAYKFAGGGRKHPRYRCRSMGFPKHCGNGTV
                     AMAEWDAFCEEQVLDLLGDAERLEKVWVAGSDSAIELAEVNAELVDLTSLIGSPAYRAG
                     SPQREALDARIAALAARQEELEGLEARPSGWEWRETGQRFGDWWREQDTAAKNTWLRSM
                     NVRLTFDVRGGLTRTIDFGDLQEYEQHLRLGSVVERLHTGMS"
     polyA_signal    3728..3862
                     /label=SV40 poly(A) signal
                     /note="SV40 polyadenylation signal"
     primer_bind     complement(3765..3784)
                     /label=SV40pA-R
                     /note="SV40 polyA, reverse primer"
     primer_bind     3819..3838
                     /label=EBV-rev
                     /note="SV40 polyA terminator, reverse primer"
     rep_origin      3988..4442
                     /direction=RIGHT
                     /label=f1 ori
                     /note="f1 bacteriophage origin of replication; arrow
                     indicates direction of (+) strand synthesis"
     primer_bind     complement(4075..4094)
                     /label=F1ori-R
                     /note="F1 origin, reverse primer"
     primer_bind     4284..4305
                     /label=F1ori-F
                     /note="F1 origin, forward primer"
     CDS             4729..5589
                     /codon_start=1
                     /gene="bla"
                     /product="beta-lactamase"
                     /label=AmpR
                     /note="confers resistance to ampicillin, carbenicillin, and
                     related antibiotics"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYI
                     ELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVEYS
                     PVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRW
                     EPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSA
                     LPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGAS
                     LIKHW"
     primer_bind     complement(4947..4966)
                     /label=Amp-R
                     /note="Ampicillin resistance gene, reverse primer"
     protein_bind    complement(5691..5724)
                     /label=loxP
                     /bound_moiety="Cre recombinase"
                     /note="Cre-mediated recombination occurs in the 8-bp core 
                     sequence (ATGTATGC) (Shaw et al., 2021)."